Functional respiratory imaging in bronchiectasis
Research type
Research Study
Full title
Functional respiratory imaging during pulmonary exacerbations in adults with bronchiectasis
IRAS ID
251721
Contact name
Timothy Baird
Contact email
Sponsor organisation
Royal Papworth Hospital NHS Foundation Trust
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 3 months, 0 days
Research summary
This study is a prospective single centre exploratory pilot study in adults with bronchiectasis.
The aim of the study is to determine whether Functional Respiratory Imaging (FRI), a novel image-based tool, can be used to assess treatment response in individuals with bronchiectasis suffering a chest exacerbation. The study will endeavor to recruit 10 adult patients who have a known diagnosis of bronchiectasis, attend the Cambridge Centre for Lung Infection at The Royal Papworth Hospital, Cambridge, and are suffering a chest exacerbation.
The study will involve 4 separate visits over a 28-day period followed by a follow-up phone call at day 35. The study will not alter the usual treatment for a chest exacerbation in any way, however will incorporate 3 trial-specific CT scans (FRI) and 2 questionnaires at days 0, 14 and 28. A summary of the study schedule is outlined below.
• Day 0: Usual treatment commencement – clinical review; sputum collection; blood test; breathing test; 2 questionnaires; CT scan (FRI)
• Day 7: Day 7 of treatment – clinical review, blood test
• Day 14: Day 14 of treatment (end of treatment) – clinical review; blood test; breathing test; 2 questionnaires; CT scan (FRI)
• Day 28: Post treatment follow up – clinical review; blood test; breathing test; 2 questionnaires; CT scan (FRI)
• Day 35: Follow up phone call – post completion of the study testing
We hypothesise that changes in FRI will be seen pre and post treatment of a chest exacerbation and will correlate well with traditional trial end points including lung function, blood markers of infection, and patient reported outcomes (questionnaires / quality of life measures). This will confirm FRI as a useful and novel tool for assessing treatment response in future clinical trials in bronchiectasis patients.
REC name
East of England - Cambridge East Research Ethics Committee
REC reference
19/EE/0006
Date of REC Opinion
5 Mar 2019
REC opinion
Further Information Favourable Opinion